TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shield Therapeutics ( (GB:STX) ) has provided an announcement.
Shield Therapeutics announced the presentation of pediatric pharmacokinetic results for ferric maltol at the upcoming American Society of Hematology Conference. The study confirmed the suitability of ferric maltol for iron replacement in children, supporting its potential expansion to younger populations and highlighting its importance in addressing unmet medical needs in pediatric iron deficiency treatment.
The most recent analyst rating on (GB:STX) stock is a Buy with a £0.10 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical performance, indicating strong market momentum. However, significant financial weaknesses, including negative profitability and cash flow issues, weigh heavily on the score. Valuation concerns due to a negative P/E ratio and lack of dividend yield further impact the stock’s attractiveness.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focusing on addressing iron deficiency through its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). The company operates in the U.S. and has partnerships for its product in various international markets, including the UK, European Union, China, and Japan.
Average Trading Volume: 4,120,504
Technical Sentiment Signal: Buy
Current Market Cap: £72.73M
For a thorough assessment of STX stock, go to TipRanks’ Stock Analysis page.